Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502864 · ClinicalTrials.gov registry record · Phase 4
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
A Phase 4 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT02502864 is a Phase 4 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT02502864, a Phase 4 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharmacokinetic (PK)-adjusted docetaxel. The researchers believe that adjusting the dose of docetaxel using this method will lessen the side effects associated with docetaxel in cancer treatment.
Interventions
- DRUG Standard of Care: Docetaxel
- DRUG Standard of Care: Cyclophosphamide
- OTHER Function Assessment of Cancer Therapy (FACT) Surveys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-02-09 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02502864
The ClinicalTrials.gov registry entry for NCT02502864 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care: Docetaxel is the first listed.
NCT02502864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02502864 about?
NCT02502864 is a clinical study titled "Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide". The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharmacokinetic (PK)-adjusted docetaxel. The researchers believe that adjusting the dose of docetaxel using this metho...
What is the current status of trial NCT02502864?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2016-02-09. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT02502864?
The interventions under investigation include: Standard of Care: Docetaxel (DRUG), Standard of Care: Cyclophosphamide (DRUG), Function Assessment of Cancer Therapy (FACT) Surveys (OTHER).
Who is sponsoring clinical trial NCT02502864?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.